• Latest Posts

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Two Big Pharma Players Team up to Take Over the NASH Space

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech


Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Finally, Pfizer acquires Botox-maker Allergan for €150Bn to move to tax-friendly Ireland!

To beat J&J, Pfizer attempts a New Merger…Guess who’s the Target this Time?!

Roche’s patent halts an Amgen biosimilar debut

Oh dear, Allergan is doing its 4th product recall in 2015 …

Allergan Continues its Serial Acquisitions to be a Giant Drugmaker